Dan Jacob Gelvan

Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel.

IntelliDx, Inc. develops medical devices. It offers automated ex vivo blood analysis systems that measure the constituents of flowing human blood, and automated blood glucose monitoring systems that measure glucose in hospitalized patients who have abnormally elevated sugar levels. The company was founded in 2000 and is headquartered in Santa Clara, CA.

Zetiq Technologies Ltd. provides non-cytotoxic anti-cancer drugs. Its products include CamaRx, CamaDx, and CamaGex. The company distributes its products throughout Israel. Zetiq Technologies was founded in 1997 and is headquartered in Ramat Gan, Israel

Aurum Ventures MKI Ltd (Aurum Ventures) is a venture capital subsidiary of Morris Kahn founded in 1998 by Morris Kahn. The firm is headquartered in Tel Aviv, Israel.

LifeBond Ltd. engages in the development of medical devices designed to restore and repair tissues to reduce post-operative complications. The company was founded by Nir Mashkif, Orahn Preiss-Bloom and Ishay Attar in 2007 and is headquartered in Caesarea, Israel.

CorAssist Cardiovascular Ltd. develops therapeutic products for treating diastolic heart failure. Its proprietary technology enables the implantation of a device that directly improves cardiac diastolic function. The firm’s product, the ImCardia, is an elastic self-expanding device that is attached to the external left ventricular surface, through a simple off-pump closed heart procedure. The company was founded by Yair Feld, Yotam Reisner and Shay Dubi in 2003 and is headquartered in Haifa, Israel.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Beta-O2 Technologies Ltd. develops implantable bio-artificial pancreas devices. It offers BAir, a bio-artificial pancreas that provides a viable environment for islets of Langerhans to thrive and provide the body with insulin on demand. The company was founded by Pnina Vardi, Konstantin Bloch, and Yossi Gross in 2004 and is headquartered in Rosh-Haayin, Israel.